Alvimopan

Drugs

Volumn 68, Issue 14, 2008, Pages 2011-2019

  Curran, Monique P ^a,b   Robyns, Gayle W ^a,b   Scott, Lesley J ^a,b   Perry, Caroline M ^a,b  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

^b WOLTERS KLUWER HEALTH   (United States)

Author keywords

Adis drug profiles; Alvimopan, general; Postoperative ileus

Indexed keywords

ALVIMOPAN; CODEINE; MORPHINE; PLACEBO; GASTROINTESTINAL AGENT; MU OPIATE RECEPTOR; NARCOTIC ANALGESIC AGENT; PIPERIDINE DERIVATIVE;

ANEMIA; BACKACHE; CLINICAL TRIAL; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG TOLERABILITY; DYSPEPSIA; GASTROINTESTINAL TRACT FUNCTION; HUMAN; HYPOKALEMIA; ILEUS; INTESTINE RESECTION; INTESTINE TRANSIT TIME; NONHUMAN; PAIN ASSESSMENT; POSTOPERATIVE PERIOD; RECOMMENDED DRUG DOSE; REVIEW; SINGLE DRUG DOSE; TREATMENT INDICATION; TREATMENT OUTCOME; URINE RETENTION; VISUAL ANALOG SCALE; ABDOMINAL SURGERY; ANIMAL; CHEMICALLY INDUCED DISORDER; DRUG ANTAGONISM; DRUG EFFECT; GASTROINTESTINAL DISEASE; GASTROINTESTINAL MOTILITY; HALF LIFE TIME; POSTOPERATIVE PAIN;

ANALGESICS, OPIOID; ANIMALS; DIGESTIVE SYSTEM SURGICAL PROCEDURES; GASTROINTESTINAL AGENTS; GASTROINTESTINAL DISEASES; GASTROINTESTINAL MOTILITY; HALF-LIFE; HUMANS; PAIN, POSTOPERATIVE; PIPERIDINES; RECEPTORS, OPIOID, MU;

EID: 53849123343     PISSN: 00126667     EISSN: 00126667     Source Type: Journal    
DOI: 10.2165/00003495-200868140-00006     Document Type: Review

References (25)

1. Behm B, Stollman N. Postoperative ileus: etiologies and interventions. Clin Gastroenterol Hepatol 2003 Apr; 1 (2): 71-80
2. Luckey A, Livingston E, Taché Y. Mechanisms and treatment of postoperative ileus. Arch Surg 2003 Mar; 138 (2): 206-14
3. Holte K, Kehlet H. Postoperative ileus: progress towards effective management. Drugs 2002; 62 (18): 2603-15
4. Kehlet H, Holte K. Review of postoperative ileus. Am J Surg 2001; 182 Suppl. 5A: 3-10S
5. Baig MK, Wexner SD. Postoperative ileus: a review. Dis Col Rectum 2004; 47 (4): 516-26
6. DeHaven-Hudkins D, DeHaven R, Little P, et al. The involvement of the mu-opioid receptor in gastrointestinal pathophysiology: therapeutic opportunities for antagonism at this receptor. Pharmacol Ther 2008; 117 (1): 162-87
7. Aldor Corporation, GlaxoSmithKline. Entereg® (alvimopan) capusules: US prescribing information [online]. Available from URL: http://www.entereg.com/ pdf/entereg.pdf [Accessed 2008 Jun 6]
8. Zimmerman DM, Gidda JS, Cantrell BE, et al. Discovery of a potent, peripherally selective trans-3,4-dimethyl-4-(3-hydroxyphenyl)piperidine opioid antagonist for the treatment of gastrointestinal motility disorders. J Med Chem 1994; 37: 2262-5
9. Zimmerman DM, Gidda JS, Cantrell BE, et al. LY246736 dihydrate: μ opioid receptor antagonist. Drugs Future 1994 Dec; 19 (12): 1078-83
10. FDA. FDA review documents for alvimopan (NDA 021775) [online]. Available from URL: http://www.fda.gov/cder/foi/nda/2008/021775_ENTEREGTOC.htm [Accessed 2008 Sep 1]
11. Liu SS, Hodgson PS, Carpenter RL, et al. ADL 8-2698, a trans-3,4-dimethyl-4-(3-hydroxyphenyl) piperidine, prevents gastrointestinal effects of intravenous morphine without affecting analgesia. Clin Pharmacol Ther 2001; 68 (1): 66-71
12. Barr W, Nguyen P, Slattery M, et al. ADL 8-2698 reverses opioid induced delay in colonic transit [abstract no. PI-7]. Clin Pharmacol Ther 2000 Feb; 67 (2): 91
13. Gonenne J, Camilleri M, Ferber I, et al. Effect of alvimopan and codeine on gastrointestinal transit: a randomized controlled study. Clin Gastroenterol Hepatol 2005 Aug; 3 (8): 784-91
14. Foss JF, Fisher DM, Schmith VD. Pharmacokinetics of alvimopan and its metabolite in healthy volunteers and patients in postoperative ileus trials. Clin Pharmacol Ther 2008 May; 83 (5): 770-6
15. Foss J, Schmith V, Wallin B. Alvimopan (Entereg™), a novel opioid antagonist, achieves active systemic concentrations [abstract no. PII-90]. Clin Pharmacol Ther 2005; 77: 74
16. Vasist L, Schmith D, Vearer D, et al. Effects of ciprofloxacin on the pharmacokinetics (PK) of alvimpoan (ALV) & its active metabolites (MET) [abstract no. PIII-80]. Clin Pharmacol Ther 2008; 83 Suppl. 1: S97
17. Schmidt WK. Alvimopan* (ADL 8-2698) is a novel peripheral opioid antagonist. Am J Surg 2001 Dec; 182 (5A Suppl.): 27-38S
18. Smart K, Churchill A, Boyle G, et al. Investigation of the CNS penetration of alvimopan and its active metabolite in mdr1a/b (-/-) knockout and control mice [abstract]. Annual Meeting of the American Association of Pharmaceutical Scientists; 2007 Nov 11-17; San Diego (CA)
19. Delaney CP, Weese JL, Hyman NH, et al. Phase III trial of alvimopan, a novel, peripherally acting, mu opioid antagonist, for postoperative ileus after major abdominal surgery. Dis Colon Rectum 2005 May 2; 48 (6): 1114-29
20. Viscusi ER, Goldstein S, Witkowski T, et al. Alvimopan, a peripherally acting mu-opioid receptor antagonist, compared with placebo in postoperative ileus after major abdominal surgery: results of a randomized, double-blind, controlled study. Surg Endosc 2006 Jan; 20 (1): 64-70
21. Wolff BG, Michelassi F, Gerkin TM, et al. Alvimopan, a novel, peripherally acting μ opioid antagonist: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial of major abdominal surgery and postoperative ileus. Ann Surg 2004 Nov; 240 (4): 728-35
22. Ludwig KA, Enker WE, Delaney CP, et al. Accelerated gastrointestinal recovery and reduced length of stay following modified preoperative dose timing with alvimopan: results of a large randomized, placebo-controlled study in partial bowel resection [abstract]. American College of Surgeons 92nd Annual Clinical Congress; 2006 Oct 8-12; Chicago (IL)
23. Büchler MW, Seiler CM, Monson JRT, et al. Clinical trial: alvimopan for the management of postoperative ileus after abdominal surgery: results of an international randomised, double-blind, multicentre, placebo-controlled clinical study. Aliment Pharmacol Ther. Epub 2008 Mar 28
24. Wolff BG, Weese JL, Ludwig KA, et al. Postoperative ileus-related morbidity profile in patients treated with alvimopan after bowel resection. J Am Coll Surg 2007 Apr; 204 (4): 609-16
25. Senagore AJ, Bauer JJ, Du W, et al. Alvimopan accelerates gastrointestinal recovery after bowel resection regardless of age, gender, race, or concomitant medication use. Surgery 2007 Oct; 142 (4): 478-86